FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma
Following an accelerated approval earlier this year, analysis of data from an ongoing confirmatory trial has shown an increased risk of death with melphalan flufenamide (Pepaxto).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Racial Disparities Persist in Multiple Myeloma Care, Outcomes
Hispanics have higher MM - related in - hospital mortality; recent decline seen in in - hospital mortality for all except NH - Blacks (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 26, 2021 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Racial Disparities Persist in Multiple Myeloma Care, Outcomes
MONDAY, July 26, 2021 -- There are persistent disparities in multiple myeloma (MM) care for non-Hispanic (NH)-Blacks and Hispanics compared with NH-Whites, according to a study published online July 18 in Leukemia& Lymphoma. Samer Al Hadidi,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2021 Category: Pharmaceuticals Source Type: news

Risk for Psoriasis Increased for Cancer Survivors
Increased risks seen for survivors of leukemia, lymphoma, multiple myeloma, skin cancer, and lung cancer in subgroup analyses (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 21, 2021 Category: Cancer & Oncology Tags: Dermatology, Internal Medicine, Oncology, Journal, Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone HORSHAM, Pa., July 12, 2021 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Co... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, DARZALEX FASPRO®, daratumumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2021 Category: Pharmaceuticals Source Type: news

FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 12, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Study: Medicare pays average of $185K per patient to treat multiple myeloma
Medicare beneficiaries with multiple myeloma incur an average of nearly $185,000 in costs billed to the government-run plan for their diagnosis and treatment, according to an analysis published Friday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 9, 2021 Category: Consumer Health News Source Type: news

Multiple Myeloma Highlights From EHA 2021 Multiple Myeloma Highlights From EHA 2021
Prof Pieter Sonneveld discusses the latest advances in multiple myeloma from EHA 2021, including novel immune approaches, management of newly diagnosed disease, and options for high-risk patients.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2021 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

Multiple Myeloma Patients May Not Mount Adequate Response to COVID Vaccine Multiple Myeloma Patients May Not Mount Adequate Response to COVID Vaccine
Patients with multiple myeloma mount a highly variable antibody response after completing the recommended two-dose COVID-19 vaccination regimen, with some not having any detectable response, according to a new study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 6, 2021 Category: Infectious Diseases Tags: Hematology-Oncology News Source Type: news

Response to COVID - 19 Vaccine Variable in Multiple Myeloma Patients
Considerable variation seen in magnitude of antibody response, from 5 to 7,882 AU/mL, following two doses of mRNA COVID - 19 vaccine (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 2, 2021 Category: Cancer & Oncology Tags: Infections, Internal Medicine, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Response to COVID-19 Vaccine Variable in Multiple Myeloma Patients
FRIDAY, July 2, 2021 -- Patients with multiple myeloma (MM) mount a highly variable antibody response after receipt of a two-dose mRNA COVID-19 vaccination regimen, according to a study published online June 28 in Cancer Cell. Oliver Van Oekelen,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 2, 2021 Category: Pharmaceuticals Source Type: news

Ga-68 PSMA-11 improves outcomes in prostate cancer patients
PET with a gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA)-11 radiotrace...Read more on AuntMinnie.comRelated Reading: Lantheus gets FDA nod for Pylarify PET agent for prostate cancer Hoag launches PET trials for prostate cancer, myeloma Novel radiotracer shows promise for prostate imaging FDA makes history with approval of Ga-68 PSMA-11 PET Point Biopharma to use Lantheus' PyL in clinical trial (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 2, 2021 Category: Radiology Source Type: news

Ex-Pentagon Chief Rumsfeld Dies of Multiple Myeloma Ex-Pentagon Chief Rumsfeld Dies of Multiple Myeloma
Rumsfeld, 88, led the Pentagon for presidents Gerald Ford and George W. Bush and was one of most influential government leaders of the first decade of the 21st century. He died at his home in Taos, NM.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Daratumumab + chemotherapy for newly diagnosed, transplant-ineligible multiple myeloma: survival benefits at acceptable cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news

Some Myeloma Patients Get No Protection From COVID - 19 Vaccines
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 30, 2021 Category: Cancer & Oncology Tags: Infections, Oncology, Pediatrics, Immunology, News, Source Type: news

Some Myeloma Patients Get No Protection From COVID-19 Vaccines
WEDNESDAY, June 30, 2021 -- Because they're often given drugs that suppress their immune systems, people battling a blood cancer known as multiple myeloma have varying responses to the COVID-19 vaccine, new research shows. Some patients had no... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 30, 2021 Category: General Medicine Source Type: news

GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer responds to standard chemotherapy. In a phase I clinical trial at Memorial Sloan Kettering Cancer Center, the galinpepimut-S vaccine, also known as GPS, has produced an impressive, anti-tumor synergy with Opdivo, based upon early data. GPS targets the WT1 protein, which is expressed in high levels of various cancers but rarely seen in normal adult cells. The protein has been especially resistant to standard chemotherapy. The vaccine works by inducing a powerfu...
Source: Asbestos and Mesothelioma News - June 29, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

EMA Panel OKs Two New Drugs for Blood Cancers EMA Panel OKs Two New Drugs for Blood Cancers
The CHMP has recommended conditional marketing authorization for idecabtagene vicleucel for multiple myeloma and tafasitamab for lymphoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Response to COVID-19 vaccines varies widely in blood cancer patients
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines--in some cases, no detectable response--pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published in Cancer Cell in June. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic researchers study potential new CAR-T cell therapy for multiple myeloma
(Mayo Clinic) Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2021 Category: International Medicine & Public Health Source Type: news

Mayo Clinic researchers study potential new CAR-T cell therapy for multiple myeloma
ROCHESTER, Minn. -- Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet."CAR-T cell therapy is a type of immunotherapy that involves harnessing the power of a person's own immune system by [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - June 25, 2021 Category: Hospital Management Source Type: news

Mayo Clinic researchers study new class of drugs to treat multiple myeloma
PHOENIX --?Mayo Clinic researchers are studying a new class of immunotherapy drugs called "bispecific antibodies" that have demonstrated potent tumor-killing activity in multiple myeloma. A paper highlighting this work was published in Blood Cancer Discovery. "CAR-T (chimeric antigen receptor-T cell therapy) cell therapy, which uses a patient's own modified immune cells to kill cancerous tumors, [...] (Source: Mayo Clinic Arizona News)
Source: Mayo Clinic Arizona News - June 14, 2021 Category: Hospital Management Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves isatuximab-irfc for multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma
Hematology / Oncology News (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

How Long Can You Live Multiple Myeloma Diagnosis
How Long Can You Live After a Multiple Myeloma Diagnosis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 11, 2021 Category: General Medicine Source Type: news

What Is Most Common Treatment for Multiple Myeloma
What Is the Most Common Treatment for Multiple Myeloma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 10, 2021 Category: General Medicine Source Type: news

What Are the Three Stages of Multiple Myeloma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 9, 2021 Category: General Medicine Source Type: news

Is Multiple Myeloma Always Fatal
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 4, 2021 Category: General Medicine Source Type: news

UC San Diego Health begins treating multiple myeloma with CAR T-cell therapy
(University of California - San Diego) As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Can a Routine Cancer Scan Flag Depression? Can a Routine Cancer Scan Flag Depression?
Whole-body imaging used routinely in cases of multiple myeloma could also flag patients with possible depression, say researchers. Maybe one day, says an expert, but not yet.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 2, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
U.S. Milestone Follows European Medicines Agency PRIME Designation for this BCMA Bispecific Antibody for the Treatment of Relapsed or Refractory Multiple Myeloma RARITAN, N.J., June 1, 2021 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharm... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, teclistamab, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 1, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors, follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. Today’s BTD marks the 11th received by Janssen’s ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlight...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Selinexor, bortezomib, dexamethasone cost effective in previously treated multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
May 24, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today follow-up data from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of the investigational product talquetamab, the only off-the-shelf T-cell redirecting bispecific antibody in clinical development to target both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells (NCT03399799).[1],[2],[3] With a median follow-up of more than six months, updated results in 30 patients with relapsed or refractory multiple myeloma treated with talquetamab by subcutaneous (SC) administration at the recommend...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen ’s Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
We reported initial findings for teclistamab at ASCO 2020, and study updates have observed a deepening of responses that have shown to be durable in a significant percentage of patients with relapsed or refractory multiple myeloma,” said Amrita Y. Krishnan, M.D., Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and Chief, Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, and study investigator. “Teclistamab exposure was sustained across the dosing interval and exceeded target levels, and consistent T-cell activation was ob...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Scottrade Founder Riney Gives $1.8M to UAMS Myeloma Center
The Paula and Rodger Riney Foundation give $1.8 million to the University of Arkansas for Medical Sciences Myeloma Center. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - May 20, 2021 Category: American Health Source Type: news

New epigenetic regulatory mechanisms involved in multiple myeloma growth
(Kumamoto University) An international team of researchers has analyzed the function of the histone demethylase KDM5A in multiple myeloma, one of the three major hematological cancers, and clarified the mechanism by which it promotes myeloma cell proliferation. They also developed a novel KDM5 inhibitor and showed that it inhibits cancer cell growth in a myeloma mouse model. The researchers expect that new therapies targeting KDM5A will be developed in the future. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2021 Category: Cancer & Oncology Source Type: news

Efficacy of BNT162b2 mRNA COVID - 19 Vaccine Lower in Patients With CLL
Second study shows lower neutralizing antibody titers against SARS - CoV - 2 after the first dose among elderly patients with multiple myeloma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 6, 2021 Category: Cancer & Oncology Tags: Infections, Oncology, Pharmacy, Journal, Source Type: news

Efficacy of BNT162b2 mRNA COVID-19 Vaccine Lower in Patients With CLL
THURSDAY, May 6, 2021 -- The BNT162b2 mRNA COVID-19 vaccine has lower efficacy among patients with chronic lymphocytic leukemia (CLL) and induces lower neutralizing antibody responses (NAbs) in elderly patients with multiple myeloma (MM) versus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2021 Category: Pharmaceuticals Source Type: news

Karyopharm taps Amgen, Pfizer veteran as CEO
Oncology-focused Karyopharm Therapeutics has a new CEO and president: Richard Paulson, who brings with him a collective 25 years of leadership experience at Pfizer, Amgen and Ipsen North America. Paulson is tasked with commercializing Karyopharm's cancer drugs, one of which has been approved by the U.S. Food and Drug Administration for the blood cancer multiple myeloma as well as diffuse large B-cell lymphoma. Karyopharm (Nasdaq: KPTI) is currently testing the same drug, an oral treatment called… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 3, 2021 Category: American Health Authors: Rowan Walrath Source Type: news

Karyopharm taps Amgen, Pfizer veteran as CEO
Oncology-focused Karyopharm Therapeutics has a new CEO and president: Richard Paulson, who brings with him a collective 25 years of leadership experience at Pfizer, Amgen and Ipsen North America. Paulson is tasked with commercializing Karyopharm's cancer drugs, one of which has been approved by the U.S. Food and Drug Administration for the blood cancer multiple myeloma as well as diffuse large B-cell lymphoma. Karyopharm (Nasdaq: KPTI) is currently testing the same drug, an oral treatment called… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 3, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Multiple Myeloma and Your Relationships
WebMD explores how multiple myeloma affects your relationships with family, friends, and significant others. (Source: WebMD Health)
Source: WebMD Health - April 22, 2021 Category: Consumer Health News Source Type: news

Hoag launches PET trials for prostate cancer, myeloma
Hoag Family Cancer Institute is launching two new clinical trials for PET radiotracers...Read more on AuntMinnie.comRelated Reading: Subtle Medical wins 1st clinical installation for SubtlePET RaySearch lands treatment planning deal in Calif. Digisonics takes Calif. order Xoft signs Hoag Memorial (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 21, 2021 Category: Radiology Source Type: news